Figure 1.

Least squares mean (LSM) change from baseline over time for: A, patient global assessment of arthritis (PtGA), B, patient assessment of arthritis pain (Pain), C, Short Form 36 health survey (SF‐36) physical component summary (PCS) score, and D, SF‐36 mental component summary (MCS) score (full analysis set, no imputation). Horizontal dotted lines represent the minimum clinically important differences (MCIDs). Arrow and vertical dotted line denote completion of advancement to tofacitinib for patients randomized to placebo. Advancement to tofacitinib was at month 3 for placebo nonresponders and at month 6 for all remaining placebo‐treated patients. BID = twice daily; * = P < 0.05; ** = P < 0.01; *** = P < 0.0001 versus placebo.